Checkpoint blockade after kidney transplantation

Lesouhaitier, Mathieu
Dudreuilh, Caroline
Tamain, Mathilde
Kanaan, Nada
Bailly, Elodie
Legoupil, Delphine
Deltombe, Clement
Perrin, Peggy
Manson, Guillaume
Vigneau, Cécile
Houot, Roch

Open link

Publication date

January 2018

DOI

10.1016/j.ejca.2018.03.019

Publisher

Elsevier BV

Abstract

Dear Editor, Immune checkpoint inhibitors (CPIs) have opened a new era in the treatment of cancer, and their indications are increasing rapidly. To date, these CPIs include anti-CTLA4 (ipilimumab), anti-Programmed Death 1 (PD1) (nivolumab, pembrolizumab) and anti-Programmed Death-Ligand 1 (PD-L1) (atezolizumab, avelumab, durvalumab) antibodies (Abs). Solid organ transplant recipients have a higher risk of neoplastic complications because of immunosuppressive treatments and oncogenic viral infections [...